Consumer products containing cannabis-derived CBN to be banned from June

A revised ordinance will ban consumer products containing cannabis-derived CBN starting in June. Only patients with specific conditions, such as intractable diseases without alternative treatments, will be allowed to use them.

The Japan Times reports that under a revised ordinance from the Ministry of Health, Labour and Welfare (MHLW), consumer products containing CBN—a substance derived from cannabis—will be banned starting in June. Access will be restricted to patients with specific conditions, such as intractable diseases with no alternative treatment options. The article, published on March 19, 2026, lists keywords including drugs, MHLW, CBN, and marijuana. This policy targets consumer products while preserving limited medical applications.

Verwandte Artikel

Illustration of Anvisa approving medical cannabis cultivation in Brazil, featuring scientists in a lab with plants and official documents.
Bild generiert von KI

Anvisa genehmigt Cannabis-Anbau für medizinische Zwecke

Von KI berichtet Bild generiert von KI

Die Nationalbehörde für Gesundheitsaufsicht (Anvisa) hat am 28. Januar 2026 Beschlüsse genehmigt, die den Cannabis-Anbau für Gesundheitsbehandlungen und Forschung erlauben, zusammen mit neuen Verabreichungswegen und Pflanzenimporten. Dieser Schritt markiert einen Fortschritt in der nationalen Produktionskette und erleichtert den Zugang zu pflanzlichen Arzneimitteln. Die Änderungen erweitern die Optionen für Patienten mit schweren Erkrankungen bei Beibehaltung strenger Beschränkungen.

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Von KI berichtet

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

The U.S. Supreme Court heard arguments in United States v. Hemani, challenging a federal law that prohibits unlawful drug users from possessing firearms. Justices from both conservative and liberal sides expressed skepticism about the statute's broad application, particularly to marijuana users. The case stems from a 2022 incident involving Ali Danial Hemani, who was convicted after admitting to frequent marijuana use.

Von KI berichtet Fakten geprüft

A statewide analysis led by the University of Colorado Boulder found that about 43% of cannabis flower products sold in Colorado listed THC levels outside the state’s ±15% accuracy threshold—most overstating potency—while 96% of concentrates matched their labels. The results point to a need for tighter testing and clearer packaging to bolster consumer trust.

Prime Minister Kim Min-seok said on Thursday, January 15, 2026, that the government will implement thorough measures to bolster safety rules on chemical goods, citing the long-running consumer goods disaster over toxic humidifier disinfectant. He emphasized that ensuring the safety and health of the people is the government's top policy priority.

Von KI berichtet

Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen